Study on hepatitis C virus new genotypes in Southeast Asia

东南亚丙型肝炎病毒新基因型研究

基本信息

批准号：
08041176
负责人：
HOTTA Hak
金额：
$ 1.54万
依托单位：
Kobe University School of Medicine
依托单位国家：
日本
项目类别：
Grant-in-Aid for international Scientific Research
财政年份：
1996
资助国家：
日本
起止时间：
1996 至无数据
项目状态：
已结题

来源：
https://kaken.nii.ac.jp/grant/KAKENHI-PROJECT-08041176/
关键词：
hepatitis C virus genotype seroepidemiology molecular epidemiology Southeast Asia lndonesia Thailand Philippines

项目摘要

Sero- and molecular epidemiological analyzes of hepatitis C virus (HCV) in Surabaya, lndonesia, were performed. Prevalence of anti-HCV antibodies was 2.3% in healthy blood donors. The prevalence was 5-times higher in those with liver dysfunction than in those without. HCV subtype 2a (HCV-2a) was most common (52%) among HCV isolates from blood donors. On the other hand, HCV-1a, -1b and -1d were associated with elevation of serum ALT levels in blood donors, suggesting a possibly more pathogenic feature of those subtypes than HCV-2a. These results would be beneficial to control posttransfusion hepatitis. In patients on maintenance hemodialysis, the prevalence of anti-HCV antibodies was 62.3%. HCV-1a and -1b (each 31%) were among the most common subtypes in this group. These results suggest an increased risk of HCV infection in hemodialysis, where preventive measures should be taken. In contrast to the case with blood donors, there was no significant difference in subtype prevalence between hemodialyzed patients with liver dysfunction and those without. Impaired immune responses of hemodialyzed patients might be responsible for the apparently decreased hepatocytic injury caused by HCV infection. In patients with HCC,the prevalence of anti-HCV antibodies was 64.7%. HCV-1b (57%) was the most common subtype, followed by HCV-1d (19%) and -2a (5%). Subtype prevalence was not different between HCC patients with advanced liver cirrhosis and those without. A novel subtype (HCV-3g) was identified, although its prevalence was rather low.Hepatitis G virus (HGV) infection in Chiang Mai, Thailand, was also studied. The prevalence of HGV RNA was 32%, 25%, 10% and 1% in intravenous drug users, hemodialyzed patients, chronic liver disease patients and blood donors, respectively. The prevalence was significantly higher in individuals with HCV infection (24%) than in those without (5%).

进行了Lndonesia苏拉巴亚丙型肝炎病毒（HCV）的血清和分子流行病学分析。健康献血者的抗HCV抗体患病率为2.3％。肝功能障碍的患病率比没有肝功能障碍的人高5倍。 HCV亚型2A（HCV-2A）中的HCV分离株中最常见（52％）。另一方面，HCV -1A，-1B和-1D与献血者的血清ALT水平升高有关，这表明这些亚型可能比HCV -2A更具致病性。这些结果对控制后灌注肝炎是有益的。在维持血液透析的患者中，抗HCV抗体的患病率为62.3％。 HCV -1A和-1B（每个31％）是该组最常见的亚型之一。这些结果表明，应采取预防措施的血液透析中HCV感染的风险增加。与献血者相反，血液聚疗法患者的肝功能障碍患者与没有的疾病之间的亚型患病率没有显着差异。血液聚会患者的免疫反应受损可能是导致HCV感染引起的肝细胞损伤显然降低的原因。在HCC患者中，抗HCV抗体的患病率为64.7％。 HCV-1B（57％）是最常见的亚型，其次是HCV-1D（19％）和-2A（5％）。 HCC晚期肝硬化患者和没有的HCC患者之间的亚型患病率没有差异。还研究了一种新型的亚型（HCV-3G），尽管它的患病率相当低。还研究了泰国清迈的肝炎病毒（HGV）感染。 HGV RNA的患病率分别为32％，25％，10％和1％的静脉吸毒者，血液溶剂患者，慢性肝病患者和献血者。 HCV感染的个体（24％）的患病率明显高于没有（5％）的患者。